Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: GlobeNewswire
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting for LX2006 in Q1 2026; aligned with FDA on flexible approach to process validation such as reduced PPQ manufacturing batches Late-breaking oral presentations at the American College of Cardiology (ACC) Annual Meeting demonstrate continued, encouraging efficacy and safety data across LX2006 and LX2020 programs Established research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy using novel, localized routes of administration Strengthened leadership team with addition of new Chief Medical Officer and senior appointments bolstering cardiac expertise Cash, cash equivalents and investments of $246.6 million expected to provide operational runway into 2028 NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, I
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely? [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics GAAP EPS of -$0.27 beats by $0.04 [Seeking Alpha]Seeking Alpha
- Lexeo Therapeutics to Participate in the Leerink Global Healthcare ConferenceGlobeNewswire
- Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]Seeking Alpha
LXEO
Earnings
- 3/30/26 - Beat
LXEO
Sec Filings
- 3/31/26 - Form S-8
- 3/30/26 - Form 10-K
- 3/30/26 - Form 8-K
- LXEO's page on the SEC website